Context and Objective. We have studied the antitumor activity of a "pyrazolo[3,4-d]pyrimidine" compound (CLM3) proposed for a multiple signal transduction inhibition [including the RET tyrosine kinase, epidermal growth factor receptor, vascular endothelial growth factor (VEGF) receptor (VEGFR) and with antiangiogenic activity], in primary anaplastic thyroid cancer (ATC) cells, in the human cell line 8305C (undifferentiated thyroid cancer) and in an ATC-cell line (AF). Design and Main Outcome Measures. CLM3 was tested: in primary ATC cells at the concentrations of 5, 10, 30, 50 μM; in 8305C cells, and in AF cells, at 1, 5, 10, 30, 50 or 100 μM; in AF cells in CD nu/nu mice. Results. CLM3 significantly inhibited proliferation of 8305C and AF cells, inducing also apoptosis. A significant reduction of proliferation with CLM3 in ATC cells (P < 0.01, ANOVA) was shown. CLM3 increased the percentage of apoptotic ATC cells dose-dependently (P < 0.001, ANOVA) and inhibited migration (P < 0.01) and invasion (P < 0.001). AF-cell line was injected sc in CD nu/nu mice and tumor masses became detectable 15 days after. CLM3 (50 mg/kg/die) inhibited significantly tumor growth (starting 16 days after the beginning of treatment). CLM3 significantly decreased the VEGF-A expression and microvessel density in AF tumor tissues. Furthermore, CLM3 inhibited EGFR, AKT and ERK1/2 phosphorylation and down-regulated cyclin D1 in 8305C and AF cells. Conclusions. The antitumor and antiangiogenic activity of a "pyrazolo[3,4-d]pyrimidine" compound (CLM3) is very promising in anaplastic thyroid cancer, opening the way to a future clinical evaluation

CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo

Antonelli A
;
Bocci G;Fallahi P;La Motta C;Ferrari S;Fioravanti A;Di Desidero T;Corti A;Materazzi G;Spinelli C;Fontanini G;Danesi R;Da Settimo F;Miccoli P
2014-01-01

Abstract

Context and Objective. We have studied the antitumor activity of a "pyrazolo[3,4-d]pyrimidine" compound (CLM3) proposed for a multiple signal transduction inhibition [including the RET tyrosine kinase, epidermal growth factor receptor, vascular endothelial growth factor (VEGF) receptor (VEGFR) and with antiangiogenic activity], in primary anaplastic thyroid cancer (ATC) cells, in the human cell line 8305C (undifferentiated thyroid cancer) and in an ATC-cell line (AF). Design and Main Outcome Measures. CLM3 was tested: in primary ATC cells at the concentrations of 5, 10, 30, 50 μM; in 8305C cells, and in AF cells, at 1, 5, 10, 30, 50 or 100 μM; in AF cells in CD nu/nu mice. Results. CLM3 significantly inhibited proliferation of 8305C and AF cells, inducing also apoptosis. A significant reduction of proliferation with CLM3 in ATC cells (P < 0.01, ANOVA) was shown. CLM3 increased the percentage of apoptotic ATC cells dose-dependently (P < 0.001, ANOVA) and inhibited migration (P < 0.01) and invasion (P < 0.001). AF-cell line was injected sc in CD nu/nu mice and tumor masses became detectable 15 days after. CLM3 (50 mg/kg/die) inhibited significantly tumor growth (starting 16 days after the beginning of treatment). CLM3 significantly decreased the VEGF-A expression and microvessel density in AF tumor tissues. Furthermore, CLM3 inhibited EGFR, AKT and ERK1/2 phosphorylation and down-regulated cyclin D1 in 8305C and AF cells. Conclusions. The antitumor and antiangiogenic activity of a "pyrazolo[3,4-d]pyrimidine" compound (CLM3) is very promising in anaplastic thyroid cancer, opening the way to a future clinical evaluation
2014
Antonelli, A; Bocci, G; Fallahi, P; La Motta, C; Ferrari, S; Mancusi, C; Fioravanti, A; Di Desidero, T; Sartini, S; Corti, A; Piaggi, S; Materazzi, G; Spinelli, C; Fontanini, G; Danesi, R; Da Settimo, F; Miccoli, P
File in questo prodotto:
File Dimensione Formato  
Antonelli 2014_JCEM_on line.pdf

non disponibili

Tipologia: Versione finale editoriale
Licenza: Importato da Ugov Ricerca - Accesso privato/ristretto
Dimensione 518.94 kB
Formato Adobe PDF
518.94 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/385868
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 49
  • ???jsp.display-item.citation.isi??? 46
social impact